Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis
Rajith K. R. Rajoli1, Henry Pertinez1, Usman Arshad1, Helen Box1, Lee Tatham1, Paul Curley1, Megan Neary1, Joanne Sharp1, Neill J. Liptrott1, Anthony Valentijn1, Christopher David1, Steve P. Rannard2, Ghaith Aljayyoussi3, Shaun H. Pennington3, Andrew Hill1, Marta Boffito4,5, Stephen A. Ward3, Saye H. Khoo1, Patrick G. Bray6, Paul M. O’Neill2, W. Dave Hong2, Giancarlo Biagini3, Andrew Owen1.
1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
2Department of Chemistry, University of Liverpool, Liverpool, L69 3BX, UK
3Centre for Drugs and Diagnostics, and Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
4Chelsea and Westminster NHS Foundation Trust and St Stephen’s AIDS Trust 4th Floor, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
5Jefferiss Research Trust Laboratories, Department of Medicine, Imperial College, London, W2 1PG, UK
6Pat Bray Electrical, 260D Orrell Road, Orrell, Wigan, WN5 8QZ, UK